Coenzyme Q From Exhibits Drug-Resistant Bacteria Eradication and Keratinocyte Inflammation Mitigation to Ameliorate Infected Atopic Dermatitis in Mouse.

Atopic dermatitis (AD) is an inflammatory skin disease that is usually accompanied by infection due to cutaneous barrier-function damage. Benzenoid compounds from are known to exhibit antibacterial and anti-inflammatory activities. This study sought to investigate the potential of benzenoids for treating bacteria-infected AD. The compounds were screened against methicillin-resistant (MRSA). Coenzyme Q (CoQ), a key ingredient in , showed the strongest MRSA growth inhibition. We further tested the inhibitory effect of CoQ on planktonic and biofilm MRSA. The work was also performed to explore the potential effectiveness of CoQ on AD using activated keratinocytes and experimental AD mice as the models. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of CoQ against MRSA were 7.81 μg/ml. CoQ was found to eradicate biofilm MRSA efficiently and reduce the biofilm thickness. CoQ killed MRSA by inhibiting DNA polymerase and topoisomerases. A proteomic assay showed that CoQ also reduced the ribosomal proteins. In the anti-inflammation study, CoQ was found to downregulate the expression of interleukin (IL)-6, chemokine (C-C motif) ligand (CCL)5, and CCL17 in HaCaT cells. CoQ at 0.5 μg/ml could recover the filaggrin decreased by HaCaT activation to the normal control. We established a bacteria-infected AD-like model in mice using ovalbumin (OVA) and topically applied MRSA. Topical CoQ delivery lessened the MRSA presence in the AD-like lesions by >90%. The erythema, barrier function, and epidermal thickness of the AD-like wounds were improved by CoQ through the reduction of IL-1β, IL-4, IL-6, IL-10, interferon (IFN)-γ, and by neutrophil infiltration in the lesional skin. CoQ is therefore regarded as effective in mitigating AD symptoms associated with bacterial load.